HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Aristolactam AIIIa

polo-like kinase 1 (Plk1) inhibitor; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cuong, Nguyen Hieu: 1 article (05/2021)
2.	Dang, Tran Huu: 1 article (05/2021)
3.	Hanh, Nguyen Thi My: 1 article (05/2021)
4.	Minh, Chau Van: 1 article (05/2021)
5.	Nguyen Hoai, Nam: 1 article (05/2021)
6.	Nguyen Xuan, Cuong: 1 article (05/2021)
7.	Nguyen, Hai Dang: 1 article (05/2021)
8.	Thi, Vien Le: 1 article (05/2021)
9.	Tran Hong Quang,: 1 article (05/2021)
10.	Tran Thi Hong, Hanh: 1 article (05/2021)

Related Diseases

1.

Neoplasms (Cancer)

05/01/2021 - "Among the isolated compounds, aristolochiaside (1), aristolactam AIIIa (2) and N-trans-sinapoyltyramine (10) exhibited strong and selective cytotoxicity on the HeLa human cancer cell line with IC50 values of 7.59 ± 1.03, 8.51 ± 1.73 and 9.77 ± 1.25 μM, respectively.[Formula: see text]."
10/01/2009 - "Our current work is expected to shed light on the potential anti-tumor mechanism of Aristolactam AIIIa, and this natural product might be possibly used as a lead compound for further developing anti-tumor drugs."
10/01/2009 - "The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation."

Related Drugs and Biologics

1.	Ligands
2.	Polo-Like Kinase 1